

**Supplemental Table 1: Ontario Health Administrative Databases Used to Capture Study Information<sup>£</sup>**

<b>Variable</b>	<b>Database</b>
Inflammatory bowel disease patients	Ontario Crohn's and Colitis Cohort (OCCC)
Hospitalizations and Surgeries	Canadian Institutes of Health Information Discharge Abstract Database (Ontario version)
Public payer drug costs	Ontario Drug Benefits
Age, Sex, Median neighbourhood household income quintile, Residential setting (rural vs. urban)	Registered Persons Database (RPDB)

<sup>£</sup> ICES data dictionary available at: <https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx>

---

**Supplemental Table 2.** Administrative Codes Used to Ascertain Patients and Study Variables<sup>£</sup>

---

Variable	Administrative Codes
IBD-related hospitalizations (ICD-9, ICD-10)	Any hospitalization with discharge diagnosis code 555.x, 556.x (ICD-9, prior to April 1, 2002), K50.x or K51.x (ICD-10, after April 1, 2002), under any of dxtype “M” (most responsible diagnosis), “1” (pre-admit co-morbidity), “2” (post-admit comorbidity), “W” (most responsible diagnosis for 1st transfer service), “X” (most responsible diagnosis for 2 <sup>nd</sup> transfer service) or “Y” (most responsible diagnosis for 3 <sup>rd</sup> transfer service). <i>Excludes</i> hospitalizations with admission category “L” (elective admission) AND intestinal resection (see codes below) within 48 hours of admission.
Intestinal resections <sup>£</sup> (CCP, CCI)	Any of the following codes under any prcode (CCP codes before April 1, 2002) or incode (CCI codes on or after April 1, 2002) category:  <b>Excision partial, small intestine (CD patients only)</b> CCP: 57.4, 57.41, 57.42, 57.43 CCI: 1.NK.87, 1.NK.87.DA, 1.NK.87.LA, 1.NK.87.DN, 1.NK.87.RE, 1.NK.87.DP, 1.NK.87.RF, 1.NK.87.DX, 1.NK.87.TF, 1.NK.87.DY, 1.NK.87.TG <b>Excision partial, large intestine</b> CCP: 57.5, 57.51, 57.52, 57.53, 57.54, 57.55, 57.56, 57.59 CCI: 1.NM.87.DA, 1.NM.87.LA, 1.NM.87.DF, 1.NM.87.RN, 1.NM.87.DE, 1.NM.87.RD, 1.NM.87.DN, 1.NM.87.RE, 1.NM.87.DX, 1.NM.87.TF, 1.NM.87.DY, 1.NM.87.TG <b>Excision partial, rectum</b> CCP: 60.3, 60.39, 60.4, 60.5, 60.51, 60.52, 60.53, 60.55, 60.59 CCI: 1.NQ.87, 1.NQ.87.LA, 1.NQ.87.DA, 1.NQ.87.RD, 1.NQ.87.DE, 1.NQ.87.TF, 1.NQ.87.DX <b>Excision total, large intestine</b> CCP: 57.6 CCI: 1.NM.89, 1.NM.89.DF, 1.NM.89.RN, 1.NM.89.DX, 1.NM.89.TF <b>Excision radical, large intestine</b> CCP: 57.6 CCI: 1.NM.91, 1.NM.91.DF, 1.NM.91.RN, 1.NM.91.DE, 1.NM.91.RD, 1.NM.91.DN, 1.NM.91.RE, 1.NM.91.DX, 1.NM.91.TF, 1.NM.91.DY, 1.NM.91.TG <b>Excision total, rectum</b> CCP: 60.3, 60.39, 60.4, 60.5, 60.51, 60.52, 60.53, 60.55, 60.59 CCI: 1.NQ.89, 1.NQ.89.SF, 1.NQ.89.KZ, 1.NQ.89.GV, 1.NQ.89.SF, 1.NQ.89.KZ, 1.NQ.89.RS, 1.NQ.89.LH, 1.NQ.89.AB, 1.NQ.89.RS, 1.NQ.89.LH

---

<sup>£</sup> ICES data dictionary available at: <https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx>

€ Adapted from validated list of CCI codes from: Ma C, Crespin M, Proulx MC, et al. Postoperative complications following colectomy for ulcerative colitis: a validation study. *BMC Gastroenterol.* 2012;12:39;  
Ma C, Moran GW, Benchimol EI, et al. Surgical Rates for Crohn's Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study. *Am J Gastroenterol.* 2017;112(12):1840-1848.

**Supplemental Table 3. Baseline Characteristics of Crohn's Disease Patients, by Quarter**

Date	N	Age Median (IQR)	Female (N, %)	Median Neighbourhood Household Income Quintile (N, %)					Urban Residence (N, %)
				Q1	Q2	Q3	Q4	Q5	
1-Jul-95	13,603	37 (29-49)	7,840 (57.6%)	2,495 (18.3%)	2,652 (19.5%)	2,752 (20.2%)	2,852 (21.0%)	2,787 (20.5%)	11,711 (86.1%)
1-Oct-95	13,967	38 (29-50)	8,056 (57.7%)	2,550 (18.3%)	2,744 (19.6%)	2,832 (20.3%)	2,926 (20.9%)	2,858 (20.5%)	30,396 (87.3%)
1-Jan-96	14,310	38 (29-50)	8,244 (57.6%)	2,527 (17.7%)	2,765 (19.3%)	2,968 (20.7%)	3,010 (21.0%)	2,941 (20.6%)	11,711 (86.1%)
1-Apr-96	14,662	38 (29-50)	8,441 (57.6%)	2,581 (17.6%)	2,857 (19.5%)	3,030 (20.7%)	3,097 (21.1%)	3,006 (20.5%)	30,396 (87.3%)
1-Jul-96	15,030	38 (29-50)	8,643 (57.5%)	2,645 (17.6%)	2,917 (19.4%)	3,117 (20.7%)	3,180 (21.2%)	3,092 (20.6%)	11,711 (86.1%)
1-Oct-96	15,386	38 (30-50)	8,846 (57.5%)	2,703 (17.6%)	2,982 (19.4%)	3,200 (20.8%)	3,261 (21.2%)	3,174 (20.6%)	30,396 (87.3%)
1-Jan-97	15,705	38 (30-50)	9,027 (57.5%)	2,728 (17.4%)	2,980 (19.0%)	3,218 (20.5%)	3,401 (21.7%)	3,274 (20.8%)	11,711 (86.1%)
1-Apr-97	16,059	38 (30-50)	9,240 (57.5%)	2,788 (17.4%)	3,042 (18.9%)	3,316 (20.6%)	3,473 (21.6%)	3,341 (20.8%)	30,396 (87.3%)
1-Jul-97	16,383	38 (30-50)	9,416 (57.5%)	2,851 (17.4%)	3,095 (18.9%)	3,399 (20.7%)	3,543 (21.6%)	3,410 (20.8%)	11,711 (86.1%)
1-Oct-97	16,714	39 (30-51)	9,603 (57.5%)	2,911 (17.4%)	3,156 (18.9%)	3,462 (20.7%)	3,616 (21.6%)	3,490 (20.9%)	30,396 (87.3%)
1-Jan-98	17,045	39 (30-51)	9,776 (57.4%)	2,925 (17.2%)	3,259 (19.1%)	3,498 (20.5%)	3,664 (21.5%)	3,604 (21.1%)	11,711 (86.1%)
1-Apr-98	17,383	39 (30-51)	9,963 (57.3%)	2,978 (17.1%)	3,339 (19.2%)	3,573 (20.6%)	3,734 (21.5%)	3,674 (21.1%)	30,396 (87.3%)
1-Jul-98	17,735	39 (30-51)	10,171 (57.3%)	3,027 (17.1%)	3,415 (19.3%)	3,648 (20.6%)	3,812 (21.5%)	3,753 (21.2%)	11,711 (86.1%)
1-Oct-98	18,037	39 (31-51)	10,329 (57.3%)	3,080 (17.1%)	3,464 (19.2%)	3,712 (20.6%)	3,894 (21.6%)	3,812 (21.1%)	30,396 (87.3%)
1-Jan-99	18,327	39 (31-51)	10,491 (57.2%)	3,188 (17.4%)	3,670 (20.0%)	3,824 (20.9%)	3,638 (19.9%)	3,899 (21.3%)	11,711 (86.1%)
1-Apr-99	18,666	39 (31-52)	10,671 (57.2%)	3,242 (17.4%)	3,757 (20.1%)	3,894 (20.9%)	3,706 (19.9%)	3,967 (21.3%)	30,396 (87.3%)
1-Jul-99	18,971	40 (31-52)	10,834 (57.1%)	3,289 (17.3%)	3,836 (20.2%)	3,952 (20.8%)	3,779 (19.9%)	4,024 (21.2%)	11,711 (86.1%)
1-Oct-99	19,275	40 (31-52)	10,995 (57.0%)	3,352 (17.4%)	3,882 (20.1%)	4,033 (20.9%)	3,843 (19.9%)	4,088 (21.2%)	30,396 (87.3%)
1-Jan-00	19,576	40 (31-52)	11,147 (56.9%)	3,344 (17.1%)	3,910 (20.0%)	4,078 (20.8%)	3,960 (20.2%)	4,177 (21.3%)	11,711 (86.1%)
1-Apr-00	19,899	40 (31-52)	11,312 (56.8%)	3,394 (17.1%)	3,973 (20.0%)	4,138 (20.8%)	4,020 (20.2%)	4,274 (21.5%)	30,396 (87.3%)
1-Jul-00	20,218	40 (31-52)	11,482 (56.8%)	3,458 (17.1%)	4,037 (20.0%)	4,196 (20.8%)	4,072 (20.1%)	4,365 (21.6%)	11,711 (86.1%)
1-Oct-00	20,574	40 (31-52)	11,680 (56.8%)	3,520 (17.1%)	4,124 (20.0%)	4,265 (20.7%)	4,128 (20.1%)	4,461 (21.7%)	30,396 (87.3%)
1-Jan-01	20,902	40 (31-52)	11,853 (56.7%)	3,517 (16.8%)	4,142 (19.8%)	4,282 (20.5%)	4,254 (20.4%)	4,580 (21.9%)	11,711 (86.1%)

1-Apr-01	21,225	40 (32-53)	12,036 (56.7%)	3,572 (16.8%)	4,216 (19.9%)	4,350 (20.5%)	4,324 (20.4%)	4,650 (21.9%)	30,396 (87.3%)
1-Jul-01	21,561	41 (32-53)	12,205 (56.6%)	3,628 (16.8%)	4,283 (19.9%)	4,418 (20.5%)	4,389 (20.4%)	4,744 (22.0%)	11,711 (86.1%)
1-Oct-01	21,930	41 (32-53)	12,411 (56.6%)	3,694 (16.8%)	4,373 (19.9%)	4,494 (20.5%)	4,466 (20.4%)	4,820 (22.0%)	30,396 (87.3%)
1-Jan-02	22,251	41 (32-53)	12,582 (56.5%)	3,707 (16.7%)	4,369 (19.6%)	4,500 (20.2%)	4,629 (20.8%)	4,942 (22.2%)	11,711 (86.1%)
1-Apr-02	22,570	41 (32-53)	12,763 (56.5%)	3,761 (16.7%)	4,438 (19.7%)	4,554 (20.2%)	4,709 (20.9%)	5,011 (22.2%)	30,396 (87.3%)
1-Jul-02	22,902	41 (32-53)	12,963 (56.6%)	3,821 (16.7%)	4,498 (19.6%)	4,627 (20.2%)	4,780 (20.9%)	5,086 (22.2%)	11,711 (86.1%)
1-Oct-02	23,212	41 (32-53)	13,127 (56.6%)	3,865 (16.7%)	4,566 (19.7%)	4,699 (20.2%)	4,838 (20.8%)	5,164 (22.2%)	30,396 (87.3%)
1-Jan-03	23,515	41 (32-53)	13,271 (56.4%)	3,822 (16.3%)	4,563 (19.4%)	4,758 (20.2%)	4,967 (21.1%)	5,282 (22.5%)	11,711 (86.1%)
1-Apr-03	23,849	42 (32-54)	13,455 (56.4%)	3,867 (16.2%)	4,639 (19.5%)	4,825 (20.2%)	5,050 (21.2%)	5,356 (22.5%)	30,396 (87.3%)
1-Jul-03	24,146	42 (32-54)	13,605 (56.3%)	3,902 (16.2%)	4,696 (19.4%)	4,898 (20.3%)	5,119 (21.2%)	5,431 (22.5%)	11,711 (86.1%)
1-Oct-03	24,499	42 (33-54)	13,785 (56.3%)	3,961 (16.2%)	4,746 (19.4%)	4,979 (20.3%)	5,205 (21.2%)	5,523 (22.5%)	30,396 (87.3%)
1-Jan-04	24,768	42 (33-54)	13,913 (56.2%)	4,326 (17.5%)	4,815 (19.4%)	4,919 (19.9%)	5,200 (21.0%)	5,363 (21.7%)	11,711 (86.1%)
1-Apr-04	25,109	42 (33-54)	14,093 (56.1%)	4,378 (17.4%)	4,883 (19.4%)	4,993 (19.9%)	5,268 (21.0%)	5,457 (21.7%)	30,396 (87.3%)
1-Jul-04	25,468	42 (33-54)	14,287 (56.1%)	4,426 (17.4%)	4,951 (19.4%)	5,066 (19.9%)	5,350 (21.0%)	5,555 (21.8%)	11,711 (86.1%)
1-Oct-04	25,783	42 (33-54)	14,467 (56.1%)	4,486 (17.4%)	5,007 (19.4%)	5,128 (19.9%)	5,434 (21.1%)	5,627 (21.8%)	30,396 (87.3%)
1-Jan-05	26,118	43 (33-54)	14,649 (56.1%)	4,451 (17.0%)	5,029 (19.3%)	5,199 (19.9%)	5,570 (21.3%)	5,707 (21.9%)	11,711 (86.1%)
1-Apr-05	26,438	43 (33-54)	14,797 (56.0%)	4,513 (17.1%)	5,084 (19.2%)	5,271 (19.9%)	5,648 (21.4%)	5,777 (21.9%)	30,396 (87.3%)
1-Jul-05	26,759	43 (33-55)	14,977 (56.0%)	4,570 (17.1%)	5,155 (19.3%)	5,339 (20.0%)	5,706 (21.3%)	5,864 (21.9%)	11,711 (86.1%)
1-Oct-05	27,072	43 (33-55)	15,152 (56.0%)	4,609 (17.0%)	5,220 (19.3%)	5,403 (20.0%)	5,790 (21.4%)	5,939 (21.9%)	30,396 (87.3%)
1-Jan-06	27,416	43 (34-55)	15,325 (55.9%)	4,614 (16.8%)	5,294 (19.3%)	5,465 (19.9%)	5,885 (21.5%)	6,007 (21.9%)	11,711 (86.1%)
1-Apr-06	27,730	43 (34-55)	15,475 (55.8%)	4,682 (16.9%)	5,346 (19.3%)	5,524 (19.9%)	5,962 (21.5%)	6,078 (21.9%)	30,396 (87.3%)
1-Jul-06	28,061	43 (34-55)	15,631 (55.7%)	4,732 (16.9%)	5,399 (19.2%)	5,596 (19.9%)	6,067 (21.6%)	6,141 (21.9%)	11,711 (86.1%)
1-Oct-06	28,388	44 (34-55)	15,812 (55.7%)	4,760 (16.8%)	5,481 (19.3%)	5,660 (19.9%)	6,149 (21.7%)	6,238 (22.0%)	30,396 (87.3%)
1-Jan-07	28,649	44 (34-55)	15,982 (55.8%)	4,802 (16.8%)	5,431 (19.0%)	5,714 (19.9%)	6,257 (21.8%)	6,299 (22.0%)	11,711 (86.1%)
1-Apr-07	28,941	44 (34-55)	16,134 (55.7%)	4,852 (16.8%)	5,486 (19.0%)	5,767 (19.9%)	6,332 (21.9%)	6,367 (22.0%)	30,396 (87.3%)
1-Jul-07	29,233	44 (34-56)	16,294	4,885	5,534	5,832	6,403	6,454	11,711

			(55.7%)	(16.7%)	(18.9%)	(20.0%)	(21.9%)	(22.1%)	(86.1%)
1-Oct-07	29,586	44 (34-56)	16,495 (55.8%)	4,940 (16.7%)	5,614 (19.0%)	5,904 (20.0%)	6,475 (21.9%)	6,542 (22.1%)	30,396 (87.3%)
1-Jan-08	29,938	44 (34-56)	16,687 (55.7%)	4,950 (16.5%)	5,692 (19.0%)	5,947 (19.9%)	6,585 (22.0%)	6,606 (22.1%)	11,711 (86.1%)
1-Apr-08	30,286	45 (35-56)	16,864 (55.7%)	5,005 (16.5%)	5,749 (19.0%)	6,021 (19.9%)	6,668 (22.0%)	6,697 (22.1%)	30,396 (87.3%)
1-Jul-08	30,730	45 (35-56)	17,083 (55.6%)	5,067 (16.5%)	5,834 (19.0%)	6,122 (19.9%)	6,773 (22.0%)	6,800 (22.1%)	11,711 (86.1%)
1-Oct-08	31,080	45 (35-56)	17,257 (55.5%)	5,131 (16.5%)	5,896 (19.0%)	6,204 (20.0%)	6,852 (22.0%)	6,875 (22.1%)	30,396 (87.3%)
1-Jan-09	31,429	45 (35-56)	17,442 (55.5%)	4,997 (15.9%)	5,948 (18.9%)	6,315 (20.1%)	7,076 (22.5%)	6,951 (22.1%)	11,711 (86.1%)
1-Apr-09	31,828	45 (35-56)	17,627 (55.4%)	5,050 (15.9%)	6,035 (19.0%)	6,401 (20.1%)	7,164 (22.5%)	7,049 (22.1%)	30,396 (87.3%)
1-Jul-09	32,248	45 (35-57)	17,840 (55.3%)	5,125 (15.9%)	6,114 (19.0%)	6,486 (20.1%)	7,256 (22.5%)	7,143 (22.2%)	11,711 (86.1%)
1-Oct-09	32,620	45 (35-57)	18,055 (55.3%)	5,168 (15.8%)	6,189 (19.0%)	6,593 (20.2%)	7,331 (22.5%)	7,224 (22.1%)	30,396 (87.3%)
1-Jan-10	32,984	46 (35-57)	18,251 (55.3%)	5,210 (15.8%)	6,319 (19.2%)	6,620 (20.1%)	7,444 (22.6%)	7,250 (22.0%)	11,711 (86.1%)
1-Apr-10	33,403	46 (35-57)	18,476 (55.3%)	5,272 (15.8%)	6,400 (19.2%)	6,717 (20.1%)	7,535 (22.6%)	7,341 (22.0%)	30,396 (87.3%)
1-Jul-10	33,775	46 (35-57)	18,695 (55.4%)	5,324 (15.8%)	6,475 (19.2%)	6,802 (20.1%)	7,620 (22.6%)	7,422 (22.0%)	11,711 (86.1%)
1-Oct-10	34,134	46 (35-57)	18,885 (55.3%)	5,370 (15.7%)	6,557 (19.2%)	6,876 (20.1%)	7,709 (22.6%)	7,493 (22.0%)	30,396 (87.3%)
1-Jan-11	34,454	46 (35-57)	19,034 (55.2%)	5,388 (15.6%)	6,574 (19.1%)	6,923 (20.1%)	7,828 (22.7%)	7,562 (21.9%)	11,711 (86.1%)
1-Apr-11	34,817	46 (36-57)	19,204 (55.2%)	5,416 (15.6%)	6,640 (19.1%)	7,000 (20.1%)	7,938 (22.8%)	7,653 (22.0%)	30,396 (87.3%)
1-Jul-11	35,182	46 (36-57)	19,407 (55.2%)	5,468 (15.5%)	6,709 (19.1%)	7,089 (20.1%)	8,044 (22.9%)	7,713 (21.9%)	11,711 (86.1%)
1-Oct-11	35,542	47 (36-58)	19,580 (55.1%)	5,529 (15.6%)	6,763 (19.0%)	7,157 (20.1%)	8,129 (22.9%)	7,814 (22.0%)	30,396 (87.3%)
1-Jan-12	35,904	47 (36-58)	19,773 (55.1%)	5,616 (15.6%)	6,815 (19.0%)	7,193 (20.0%)	8,264 (23.0%)	7,845 (21.8%)	11,711 (86.1%)

**Supplemental Table 4. Baseline Characteristics of Ulcerative Colitis Patients, by Quarter**

Date	N	Age Median (IQR)	Female (N, %)	Median Neighbourhood Household Income Quintile (N, %)					Urban Residence (N, %)
				Q1	Q2	Q3	Q4	Q5	
									16,433 (87.0%)
1-Apr-00	18,894	45 (35-59)	9,251 (49.0%)	2,902 (15.4%)	3,572 (18.9%)	3,840 (20.3%)	4,093 (21.7%)	4,394 (23.3%)	16,433 (87.0%)
1-Jul-00	19,257	45 (36-59)	9,439 (49.0%)	2,976 (15.5%)	3,649 (18.9%)	3,902 (20.3%)	4,169 (21.6%)	4,475 (23.2%)	16,433 (87.0%)
1-Oct-00	19,574	45 (36-59)	9,606 (49.1%)	3,028 (15.5%)	3,708 (18.9%)	3,962 (20.2%)	4,253 (21.7%)	4,549 (23.2%)	16,433 (87.0%)
1-Jan-01	19,890	46 (36-59)	9,775 (49.1%)	3,029 (15.2%)	3,689 (18.5%)	4,018 (20.2%)	4,409 (22.2%)	4,646 (23.4%)	16,433 (87.0%)
1-Apr-01	20,264	46 (36-59)	9,970 (49.2%)	3,106 (15.3%)	3,748 (18.5%)	4,109 (20.3%)	4,484 (22.1%)	4,721 (23.3%)	16,433 (87.0%)
1-Jul-01	20,658	46 (36-59)	10,152 (49.1%)	3,163 (15.3%)	3,832 (18.5%)	4,184 (20.3%)	4,575 (22.1%)	4,809 (23.3%)	16,433 (87.0%)
1-Oct-01	20,986	46 (36-59)	10,338 (49.3%)	3,213 (15.3%)	3,891 (18.5%)	4,251 (20.3%)	4,664 (22.2%)	4,880 (23.3%)	16,433 (87.0%)
1-Jan-02	21,308	46 (36-59)	10,502 (49.3%)	3,196 (15.0%)	3,929 (18.4%)	4,292 (20.1%)	4,754 (22.3%)	5,024 (23.6%)	16,433 (87.0%)
1-Apr-02	21,641	46 (36-59)	10,670 (49.3%)	3,222 (14.9%)	3,998 (18.5%)	4,369 (20.2%)	4,834 (22.3%)	5,108 (23.6%)	16,433 (87.0%)
1-Jul-02	22,034	46 (37-60)	10,876 (49.4%)	3,284 (14.9%)	4,072 (18.5%)	4,447 (20.2%)	4,928 (22.4%)	5,200 (23.6%)	16,433 (87.0%)
1-Oct-02	22,384	47 (37-60)	11,036 (49.3%)	3,346 (14.9%)	4,143 (18.5%)	4,520 (20.2%)	5,002 (22.3%)	5,290 (23.6%)	16,433 (87.0%)
1-Jan-03	22,724	47 (37-60)	11,205 (49.3%)	3,356 (14.8%)	4,081 (18.0%)	4,595 (20.2%)	5,169 (22.7%)	5,386 (23.7%)	16,433 (87.0%)
1-Apr-03	23,091	47 (37-60)	11,390 (49.3%)	3,419 (14.8%)	4,161 (18.0%)	4,663 (20.2%)	5,253 (22.7%)	5,468 (23.7%)	16,433 (87.0%)
1-Jul-03	23,460	47 (37-60)	11,567 (49.3%)	3,488 (14.9%)	4,219 (18.0%)	4,736 (20.2%)	5,349 (22.8%)	5,554 (23.7%)	16,433 (87.0%)
1-Oct-03	23,794	47 (37-60)	11,740 (49.3%)	3,534 (14.9%)	4,278 (18.0%)	4,812 (20.2%)	5,425 (22.8%)	5,647 (23.7%)	16,433 (87.0%)
1-Jan-04	24,139	47 (37-60)	11,923 (49.4%)	3,837 (15.9%)	4,493 (18.6%)	4,937 (20.5%)	5,242 (21.7%)	5,519 (22.9%)	16,433 (87.0%)
1-Apr-04	24,504	47 (37-60)	12,124 (49.5%)	3,894 (15.9%)	4,570 (18.7%)	5,009 (20.4%)	5,328 (21.7%)	5,603 (22.9%)	16,433 (87.0%)
1-Jul-04	24,858	48 (37-60)	12,308 (49.5%)	3,944 (15.9%)	4,633 (18.6%)	5,074 (20.4%)	5,410 (21.8%)	5,699 (22.9%)	16,433 (87.0%)
1-Oct-04	25,213	48 (38-60)	12,488 (49.5%)	4,003 (15.9%)	4,699 (18.6%)	5,148 (20.4%)	5,486 (21.8%)	5,783 (22.9%)	16,433 (87.0%)
1-Jan-05	25,581	48 (38-60)	12,671 (49.5%)	4,034 (15.8%)	4,741 (18.5%)	5,220 (20.4%)	5,551 (21.7%)	5,914 (23.1%)	16,433 (87.0%)
1-Apr-05	25,975	48 (38-60)	12,861 (49.5%)	4,103 (15.8%)	4,823 (18.6%)	5,292 (20.4%)	5,634 (21.7%)	6,006 (23.1%)	16,433 (87.0%)
1-Jul-05	26,381	48 (38-60)	13,086 (49.6%)	4,165 (15.8%)	4,899 (18.6%)	5,395 (20.5%)	5,733 (21.7%)	6,079 (23.0%)	16,433 (87.0%)

1-Oct-05	26,750	48 (38-61)	13,291 (49.7%)	4,220 (15.8%)	4,958 (18.5%)	5,475 (20.5%)	5,835 (21.8%)	6,165 (23.0%)	16,433 (87.0%)
1-Jan-06	27,152	48 (38-61)	13,491 (49.7%)	4,208 (15.5%)	4,990 (18.4%)	5,510 (20.3%)	5,950 (21.9%)	6,365 (23.4%)	16,433 (87.0%)
1-Apr-06	27,602	48 (38-61)	13,716 (49.7%)	4,267 (15.5%)	5,098 (18.5%)	5,598 (20.3%)	6,053 (21.9%)	6,472 (23.4%)	16,433 (87.0%)
1-Jul-06	28,024	49 (38-61)	13,943 (49.8%)	4,325 (15.4%)	5,184 (18.5%)	5,687 (20.3%)	6,153 (22.0%)	6,566 (23.4%)	16,433 (87.0%)
1-Oct-06	28,387	49 (38-61)	14,126 (49.8%)	4,393 (15.5%)	5,247 (18.5%)	5,777 (20.4%)	6,217 (21.9%)	6,648 (23.4%)	16,433 (87.0%)
1-Jan-07	28,704	49 (38-61)	14,311 (49.9%)	4,363 (15.2%)	5,209 (18.1%)	5,883 (20.5%)	6,385 (22.2%)	6,711 (23.4%)	16,433 (87.0%)
1-Apr-07	29,094	49 (38-61)	14,489 (49.8%)	4,425 (15.2%)	5,305 (18.2%)	5,946 (20.4%)	6,470 (22.2%)	6,810 (23.4%)	16,433 (87.0%)
1-Jul-07	29,531	49 (39-61)	14,702 (49.8%)	4,489 (15.2%)	5,390 (18.3%)	6,041 (20.5%)	6,565 (22.2%)	6,918 (23.4%)	16,433 (87.0%)
1-Oct-07	29,885	49 (39-61)	14,894 (49.8%)	4,539 (15.2%)	5,462 (18.3%)	6,117 (20.5%)	6,644 (22.2%)	7,011 (23.5%)	16,433 (87.0%)
1-Jan-08	30,262	49 (39-61)	15,089 (49.9%)	4,546 (15.0%)	5,428 (17.9%)	6,191 (20.5%)	6,813 (22.5%)	7,133 (23.6%)	16,433 (87.0%)
1-Apr-08	30,650	49 (39-61)	15,276 (49.8%)	4,617 (15.1%)	5,503 (18.0%)	6,256 (20.4%)	6,894 (22.5%)	7,241 (23.6%)	16,433 (87.0%)
1-Jul-08	31,132	50 (39-61)	15,506 (49.8%)	4,692 (15.1%)	5,601 (18.0%)	6,345 (20.4%)	7,000 (22.5%)	7,363 (23.7%)	16,433 (87.0%)
1-Oct-08	31,591	50 (39-62)	15,752 (49.9%)	4,749 (15.0%)	5,696 (18.0%)	6,435 (20.4%)	7,109 (22.5%)	7,487 (23.7%)	16,433 (87.0%)
1-Jan-09	31,934	50 (39-62)	15,939 (49.9%)	4,608 (14.4%)	5,730 (17.9%)	6,495 (20.3%)	7,224 (22.6%)	7,735 (24.2%)	16,433 (87.0%)
1-Apr-09	32,384	50 (39-62)	16,168 (49.9%)	4,678 (14.4%)	5,810 (17.9%)	6,619 (20.4%)	7,317 (22.6%)	7,827 (24.2%)	16,433 (87.0%)
1-Jul-09	32,897	50 (39-62)	16,429 (49.9%)	4,743 (14.4%)	5,902 (17.9%)	6,719 (20.4%)	7,434 (22.6%)	7,974 (24.2%)	16,433 (87.0%)
1-Oct-09	33,304	50 (39-62)	16,629 (49.9%)	4,796 (14.4%)	5,974 (17.9%)	6,814 (20.5%)	7,532 (22.6%)	8,068 (24.2%)	16,433 (87.0%)
1-Jan-10	33,715	50 (39-62)	16,845 (50.0%)	4,809 (14.3%)	6,086 (18.1%)	6,922 (20.5%)	7,664 (22.7%)	8,111 (24.1%)	16,433 (87.0%)
1-Apr-10	34,170	50 (39-62)	17,092 (50.0%)	4,878 (14.3%)	6,185 (18.1%)	7,008 (20.5%)	7,759 (22.7%)	8,217 (24.0%)	16,433 (87.0%)
1-Jul-10	34,598	50 (39-62)	17,324 (50.1%)	4,932 (14.3%)	6,280 (18.2%)	7,094 (20.5%)	7,872 (22.8%)	8,299 (24.0%)	16,433 (87.0%)
1-Oct-10	35,023	51 (40-62)	17,533 (50.1%)	5,003 (14.3%)	6,364 (18.2%)	7,172 (20.5%)	7,963 (22.7%)	8,402 (24.0%)	16,433 (87.0%)
1-Jan-11	35,435	51 (40-62)	17,753 (50.1%)	5,070 (14.3%)	6,412 (18.1%)	7,204 (20.3%)	8,092 (22.8%)	8,502 (24.0%)	16,433 (87.0%)
1-Apr-11	35,901	51 (40-62)	17,989 (50.1%)	5,150 (14.3%)	6,475 (18.0%)	7,301 (20.3%)	8,194 (22.8%)	8,629 (24.0%)	16,433 (87.0%)
1-Jul-11	36,402	51 (40-63)	18,250 (50.1%)	5,218 (14.3%)	6,574 (18.1%)	7,410 (20.4%)	8,316 (22.8%)	8,737 (24.0%)	16,433 (87.0%)
1-Oct-11	36,827	51 (40-63)	18,475 (50.2%)	5,280 (14.3%)	6,629 (18.0%)	7,504 (20.4%)	8,425 (22.9%)	8,848 (24.0%)	16,433 (87.0%)
1-Jan-12	37,210	51 (40-63)	18,651	5,280	6,768	7,580	8,508	8,912	16,433



			(50.1%)	(14.2%)	(18.2%)	(20.4%)	(22.9%)	(24.0%)	(87.0%)
--	--	--	---------	---------	---------	---------	---------	---------	---------

<b>Supplemental Table 5. Output from ITS Analysis with Segmented Regression for Quarterly Rates of IBD-Related Hospitalizations Among Crohn's Disease Patients<sup>€</sup></b>			
	All Patients	Infliximab Users	Infliximab Non-Users
<b>Outcome</b>	<b>Odds Ratio (95% CI)</b>	<b>Odds Ratio (95% CI)</b>	<b>Odds Ratio (95% CI)</b>
Pre-Interruption Slope <sup>a</sup>	0.980 (0.975, 0.985)	0.986 (0.982, 0.990)	0.979 (0.974, 0.984)
Change in Intercept <sup>b</sup>	0.929 (0.849, 1.02)	1.15 (1.06, 1.24)	0.866 (0.783, 0.959)
Change in Slope <sup>c</sup>	1.00 (0.998, 1.01)	1.00 (0.995, 1.01)	1.01 (0.997, 1.01)
Combined Effect <sup>d</sup>	1.06 (0.811, 1.39)	1.13 (0.885, 1.45)	0.979 (0.723, 1.33)

<sup>€</sup>Outcomes based on a 10-year post-interruption observation period

<sup>a</sup>Estimates reflect OR across successive quarters prior to marketplace infliximab introduction

<sup>b</sup>Estimates reflect the OR for the *difference* in intercept following marketplace infliximab introduction (immediate effect)

<sup>c</sup>Estimates reflect the quarter-to-quarter *difference* in OR between the observed and expected slopes following marketplace infliximab introduction (gradual effect)

<sup>d</sup>Estimates reflect the combined effects of *differences* in intercept and slope at the last observation quarter following marketplace infliximab introduction (observed minus counterfactual)

<b>Supplemental Table 6. Output from ITS Analysis with Segmented Regression for Quarterly Rates of IBD-Related Hospitalizations Among Ulcerative Colitis Patients<sup>€</sup></b>			
	All Patients	Infliximab Users	Infliximab Non-Users
<b>Outcome</b>	<b>Odds Ratio (95% CI)</b>	<b>Odds Ratio (95% CI)</b>	<b>Odds Ratio (95% CI)</b>
Pre-Interruption Slope <sup>a</sup>	0.980 (0.975, 0.985)	0.976 (0.973, 0.979)	0.972 (0.969, 0.976)
Change in Intercept <sup>b</sup>	0.929 (0.849, 1.02)	0.922 (0.849, 1.00)	0.884 (0.811, 0.963)
Change in Slope <sup>c</sup>	1.00 (0.998, 1.01)	1.01 (1.01, 1.02)	1.01 (1.01, 1.02)
Combined Effect <sup>d</sup>	1.06 (0.811, 1.39)	1.22 (1.07, 1.39)	1.18 (1.03, 1.35)

<sup>€</sup>Outcomes based on a 5-year post-interruption observation period

<sup>a</sup>Estimates reflect OR across successive quarters prior to marketplace infliximab introduction

<sup>b</sup>Estimates reflect the OR for the *difference* in intercept following marketplace infliximab introduction (immediate effect)

<sup>c</sup>Estimates reflect the quarter-to-quarter *difference* in OR between the observed and expected slopes following marketplace infliximab introduction (gradual effect)

<sup>d</sup>Estimates reflect the combined effects of *differences* in intercept and slope at the last observation quarter following marketplace infliximab introduction (observed minus counterfactual)

<b>Supplemental Table 7. Output from ITS Analysis with Segmented Regression for Quarterly Rates of Intestinal Resections Among Crohn's Disease Patients<sup>€</sup></b>			
	All Patients	Infliximab Users	Infliximab Non-Users
<b><i>Outcome</i></b>	<b><i>Odds Ratio (95% CI)</i></b>	<b><i>Odds Ratio (95% CI)</i></b>	<b><i>Odds Ratio (95% CI)</i></b>
Pre-Interruption Slope <sup>a</sup>	0.984 (0.979, 0.99)	0.996 (0.989, 1.01)	0.983 (0.977, 0.989)
Change in Intercept <sup>b</sup>	0.962 (0.869, 1.07)	1.04 (0.813, 1.34)	0.941 (0.845, 1.05)
Change in Slope <sup>c</sup>	1.00 (0.997, 1.01)	0.990 (0.975, 1.01)	1.00 (0.998, 1.01)
Combined Effect <sup>d</sup>	1.10 (0.810, 1.50)	0.672 (0.315, 1.43)	1.14 (0.820, 1.58)

<sup>€</sup>Outcomes based on a 10-year post-interruption observation period

<sup>a</sup>Estimates reflect OR across successive quarters prior to marketplace infliximab introduction

<sup>b</sup>Estimates reflect the OR for the *difference* in intercept following marketplace infliximab introduction (immediate effect)

<sup>c</sup>Estimates reflect the quarter-to-quarter *difference* in OR between the observed and expected slopes following marketplace infliximab introduction (gradual effect)

<sup>d</sup>Estimates reflect the combined effects of *differences* in intercept and slope at the last observation quarter following marketplace infliximab introduction (observed minus counterfactual)

<b>Supplemental Table 8. Output from ITS Analysis with Segmented Regression for Quarterly Rates of Colectomies Among Ulcerative Colitis Patients<sup>€</sup></b>			
	All Patients	Infliximab Users	Infliximab Non-Users
<b>Outcome</b>	<b>Odds Ratio (95% CI)</b>	<b>Odds Ratio (95% CI)</b>	<b>Odds Ratio (95% CI)</b>
Pre-Interruption Slope <sup>a</sup>	0.993 (0.975, 1.01)	1.00 (0.889, 1.13)	0.995 (0.976, 1.01)
Change in Intercept <sup>b</sup>	1.29 (1.09, 1.52)	1.35 (0.536, 3.40)	1.30 (1.10, 1.53)
Change in Slope <sup>c</sup>	0.987 (0.967, 1.01)	1.05 (0.922, 1.19)	0.982 (0.962, 1.00)
Combined Effect <sup>d</sup>	0.933 (0.540, 1.61)	4.17 (0.145, 119)	0.841 (0.487, 1.45)

<sup>€</sup>Outcomes based on a 5-year post-interruption observation period

<sup>a</sup>Estimates reflect OR across successive quarters prior to marketplace infliximab introduction

<sup>b</sup>Estimates reflect the OR for the *difference* in intercept following marketplace infliximab introduction (immediate effect)

<sup>c</sup>Estimates reflect the quarter-to-quarter *difference* in OR between the observed and expected slopes following marketplace infliximab introduction (gradual effect)

<sup>d</sup>Estimates reflect the combined effects of *differences* in intercept and slope at the last observation quarter following marketplace infliximab introduction (observed minus counterfactual)

<b>Supplemental Table 9. Output from ITS Analysis with Segmented Regression for Quarterly Public Payer Prescription Drug Costs Among Crohn's Disease Patients<sup>€</sup></b>			
	All Patients	Infliximab Users	Infliximab Non-Users
<b>Outcome</b>	<b>Relative Change (95% CI)</b>	<b>Relative Change (95% CI)</b>	<b>Relative Change (95% CI)</b>
Pre-Interruption Slope <sup>a</sup>	1.01 (1.01, 1.02)	1.02 (1.00, 1.03)	1.01 (1.00, 1.02)
Change in Intercept <sup>b</sup>	1.34 (1.28, 1.41)	3.486 (3.00, 4.05)	1.09 (1.04, 1.15)
Change in Slope <sup>c</sup>	1.02 (1.01, 1.02)	1.02 (1.01, 1.04)	1.00 (1.00, 1.01)
Combined Effect <sup>d</sup>	2.98 (2.29, 3.86)	9.49 (4.45, 20.3)	1.17 (0.875, 1.57)

<sup>€</sup>Outcomes based on a 10-year post-interruption observation period

<sup>a</sup>Estimates reflect relative change across successive quarters prior to marketplace infliximab introduction

<sup>b</sup>Estimates reflect the relative change for the *difference* in intercept following marketplace infliximab introduction (immediate effect)

<sup>c</sup>Estimates reflect the quarter-to-quarter *difference* in relative change between the observed and expected slopes following marketplace infliximab introduction (*gradual effect*)

<sup>d</sup>Estimates reflect the combined effects of *differences* in intercept and slope at the last observation quarter following marketplace infliximab introduction (observed minus counterfactual)

<b>Supplemental Table 10. Output from ITS Analysis with Segmented Regression for Quarterly Public Payer Prescription Drug Costs Among Ulcerative Colitis Patients<sup>€</sup></b>			
	All Patients	Infliximab Users	Infliximab Non-Users
<b>Outcome</b>	<b>Relative Change (95% CI)</b>	<b>Relative Change (95% CI)</b>	<b>Relative Change (95% CI)</b>
Pre-Interruption Slope <sup>a</sup>	1.01 (1.01, 1.02)	1.04 (1.03, 1.06)	1.01 (1.01, 1.02)
Change in Intercept <sup>b</sup>	1.00 (0.968, 1.03)	1.47 (1.24, 1.74)	1.03 (0.992, 1.06)
Change in Slope <sup>c</sup>	1.00 (0.998, 1.01)	1.01 (0.99, 1.03)	0.989 (0.985, 0.993)
Combined Effect <sup>d</sup>	1.06 (0.955, 1.18)	1.88 (1.14, 3.12)	0.790 (0.704, 0.886)

<sup>€</sup>Outcomes based on a 5-year post-interruption observation period

<sup>a</sup>Estimates reflect relative change across successive quarters prior to marketplace infliximab introduction

<sup>b</sup>Estimates reflect the relative change for the *difference* in intercept following marketplace infliximab introduction (immediate effect)

<sup>c</sup>Estimates reflect the quarter-to-quarter *difference* in relative change between the observed and expected slopes following marketplace infliximab introduction (*gradual effect*)

<sup>d</sup>Estimates reflect the combined effects of *differences* in intercept and slope at the last observation quarter following marketplace infliximab introduction (*observed minus counterfactual*)